Last update June 2, 2022
Solriamfetol is a central stimulant with actions similar to modafinil, although they are not structurally related. Selectively inhibits the reuptake of dopamine and norepinephrine. It is used in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Oral administration once daily.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data do not allow to predict its possible excretion in breast milk. Its low protein binding and low molecular weight would favor it, but the high volume of distribution would prevent it.
The manufacturer (Jazz 2021, FDA 2019) and expert authors (LactMed) consider its administration possible during lactation, monitoring the infant for signs of irritability, insomnia, diarrhea, appetite and adequate weight gain.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM